Enveric Biosciences News

'Psychedelics-Inspired' Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand

Enveric Biosciences (NASDAQ:ENVB) reported it financial results on Wednesday for the first quarter of 2024 ended March 31, 2024."We believe the first quarter of 2024 was a highly productive period for

BenzingaMay 16 10:25

Enveric Biosciences | 10-Q: Quarterly report

SEC announcementMay 15 12:00 · Announcements

Enveric Biosciences Q1 2024 GAAP EPS $(0.61) Beats $(0.78) Estimate

Enveric Biosciences (NASDAQ:ENVB) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.78) by 21.79 percent.

BenzingaMay 15 05:11

Enveric Biosciences Had Cash-On-Hand of $6.36M for the Qtr Ended March 31 >ENVB

Enveric Biosciences Had Cash-On-Hand of $6.36M for the Qtr Ended March 31 >ENVB

Dow JonesMay 15 05:01

Enveric Biosciences 1Q Loss/Shr 61c >ENVB

Enveric Biosciences 1Q Loss/Shr 61c >ENVB

Dow JonesMay 15 05:01

Enveric Biosciences 1Q Loss $2.46M >ENVB

Enveric Biosciences 1Q Loss $2.46M >ENVB

Dow JonesMay 15 05:01

Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results

Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the first quarter of 2024 ended March 31, 2024.

BusinesswireMay 15 05:00

Firefly Neuroscience Names David Johnson Executive Chairman, Following WaveDancer Merger

Firefly Neuroscience has appointed David Johnson as its executive chairman following completion of its planned merger with WaveDancer (WAVD), Firefly Neuroscience said Tuesday. Johnson formerly held r

MT NewswiresMay 14 10:11

Enveric Biosciences Signs $66.5M Non-binding Term Sheet With MindBio Therapeutics

Seeking AlphaMay 14 08:27

Enveric Biosciences Announces Signing of Non-Binding Term Sheet With Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids

Enveric Biosciences, Inc (NASDAQ: ENVB), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has signed a non-binding term sheet with an undisclosed biotechnology development and commercialization company ("Licensee") to exclusively out-license two patent families of Methods for Treating Breast Cancer and Other Cancers for development through additional discovery and preclinical stages using cannabinoids in combination with chemotherapeutic drugs to treat cancer.

BusinesswireMay 8 06:00

"FDA Expert Committee Will Review MDMA-Assisted Therapy For PTSD Next Month" - Marijuana Moment

The Food and Drug Administration (FDA) is taking the next step in its historic review of MDMA-assisted therapy for the treatment of post-traumatic stress disorder (PTSD), scheduling a meeting next mon

BenzingaMay 7 10:54

Enveric Biosciences, Inc. (ENVB) Stock Declines While Market Improves: Some Information for Investors

Yahoo FinanceApr 26 16:50

What Makes Enveric Biosciences (ENVB) a New Strong Buy Stock

Yahoo FinanceApr 12 11:00

FibroGen, Acorda Therapeutics, Enveric Biosciences Among Healthcare Movers

Seeking AlphaApr 3 09:00

SOL, MESO and ACOR Among Pre-market Losers

Seeking AlphaApr 3 07:12

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

GainersARCA biopharma (NASDAQ:ABIO) stock moved upwards by 124.6% to $3.84 during Wednesday's pre-market session. The market value of their outstanding shares is at $55.6 million. Kintara Therapeutics

BenzingaApr 3 07:09

Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence

Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant DepressionPartners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a P

BenzingaMar 29 11:43

Enveric Biosciences Optimistic On Q4 And Full-Year Results: 'Psychedelic-Inspired' Meds For Future Growth

Nasdaq-listed psychedelics biotech Enveric Biosciences (NASDAQ:ENVB) shared its financial results for the fourth quarter of 2023 and the fiscal year ended December 31, 2023, results showing:Cash in ha

BenzingaMar 27 07:59

Enveric Biosciences Reports Q4 Results

Seeking AlphaMar 26 07:43

Enveric Biosciences 4Q Loss/Shr $1.46 >ENVB

Enveric Biosciences 4Q Loss/Shr $1.46 >ENVB

Dow JonesMar 26 06:02